AzTrials
AzTrials

Multiple MyelomaPhase 1MagnetisMM-20NCT05675449

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

A Phase 1 study testing Elranatamab, Carfilzomib and Maplirpacept in people with Multiple Myeloma, run by Pfizer at 36 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Myeloma
What is being tested?
Elranatamab, Carfilzomib and Maplirpacept
Could I receive a placebo?
No, everyone receives an active treatment
How many people
59 participants
Where
36 sitesin 2 countries
Study dates
14 Dec 2022to 29 Feb 2028
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Prior diagnosis of multiple myeloma as defined by IMWG criteria.
  • Measurable disease based on IMWG criteria as defined by at least 1 of the following:
  • Serum M-protein ≥0.5 g/dL.
  • Urinary M-protein excretion ≥200 mg/24 hours.
  • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
  • Part 1: Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy).
Show all 10Show fewer
  • Part 2: Received at least 3 prior lines of therapy for multiple myeloma who are refractory to at least one IMiD, one PI and one anti-CD38 antibody.
  • ECOG performance status 0-1.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.
  • Not pregnant or breastfeeding and willing to use contraception.

Who cannot join

  • Plasma cell leukemia, Smouldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome, Primary refractory MM
  • Impaired cardiovascular function or clinically significant cardiovascular diseases.
  • Participants with any active, uncontrolled bacterial, fungal, or viral infection.
  • Stem cell transplant within 12 weeks prior to enrollment, or active graft versus host disease.
  • Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Part 1: Previous treatment with a BCMA-directed therapy.
Show all 12Show fewer
  • Part 2: Previous treatment with any anti-BCMA directed therapy, with the exception of CAR-T. Previous treatment with a CD47-SIRP alpha-directed therapy.
  • Part 1: Prior treatment with carfilzomib
  • Live attenuated vaccine within 4 weeks of the first dose of study intervention.
  • Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.
  • Any of the following within 3 months of enrollment: erosive esophagitis, treatment resistant peptic ulcer, infectious or inflammatory bowel disease, pulmonary embolism or uncontrolled thromboembolic event.
  • Intolerance to or participants who have had a severe (Grade ≥3) allergic or anaphylactic reaction to antibodies or therapeutic proteins

Trial locations and contacts

36 sites in 2 countries.

36 sites in 2 countries

United States31 sites

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308

  • Emory University Administration Office

    Atlanta, Georgia, 30322

  • Emory University Hospital

    Atlanta, Georgia, 30322

  • Winship Cancer Institute

    Atlanta, Georgia, 30322

  • Sylvester Comprehensive Cancer Center - Aventura

    Aventura, Florida, 33180

  • Oncology Investigational Drug Service,Department of Pharmacy Services

    Baltimore, Maryland, 21231

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21231

  • Johns Hopkins University Cancer Immunology/GI Oncology

    Baltimore, Maryland, 21287

  • Beverly Hills Cancer Center

    Beverly Hills, California, 90211

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

  • Dana Farber/Mass General Brigham Cancer Care, Inc

    Boston, Massachusetts, 02115

  • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center

    Coral Gables, Florida, 33146

  • Sylvester Comprehensive Cancer Center - Coral Springs

    Coral Springs, Florida, 33065

  • University of Miami Hospital and Clinics - Deerfield Beach

    Deerfield Beach, Florida, 33442

  • Clinical Research Advisors (Encino Satellite Location)

    Encino, California, 91316

  • Sylvester Comprehensive Cancer Center - Hollywood

    Hollywood, Florida, 33021

  • State University of Iowa, Division of Sponsored Programs

    Iowa City, Iowa, 52242

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205

  • Clinical Research Advisors (Korea Town Satellite Location)

    Los Angeles, California, 90020

  • Clinical Research Advisors (West Hollywood Satellite Location)

    Los Angeles, California, 90048

  • Griffin Cancer Research Building (GCRB)

    Miami, Florida, 33136

  • Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136

  • University of Miami Hospital and Clinics

    Miami, Florida, 33136

  • Sylvester Comprehensive Cancer Center - Kendall

    Miami, Florida, 33176

  • MSK Monmouth

    Middletown, New Jersey, 07748

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee, 37232

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York, 10021

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York, 10065

  • Sylvester Comprehensive Cancer Center - Plantation

    Plantation, Florida, 33324

Other trials in United States

Israel5 sites

  • Rambam Health Care Campus

    Haifa, 3109601

  • Division of Hematology Hadassah Medical Center - Ein Kerem

    Jerusalem, 9112001

  • The Research Fund of Hadassah Medical Organization (R.A.)

    Jerusalem, 9112001

  • Hematology Division Davidoff Center, Rabin Medical Center, Beilinson Hospital

    Petah Tikva, 4941492

  • Rabin Medical Center

    Petah Tikva, 4941492

Other trials in Israel

About this study

Official title: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept.

There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept.

Read more

All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein)

The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.

Being tested
Elranatamab, Carfilzomib, Maplirpacept
Keywords
elranatamab, relapsed, RRMM, BCMA, C1071020, MagnetisMM, maplipacelt, PF-06863135, carfilzomib, Bispecific antibody, PF-07901801, TTI-622, SIRPα, CD47
Medical subject headings
Multiple Myeloma, Recurrence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ElranatamabDrug

    Also called PF-06863135

    BCMA-CD3 bispecific antibody

  • CarfilzomibDrug

    Also called Kyprolis

    proteasome inhibitor

  • MaplirpaceptDrug

    Also called PF-07901801, TTI-622

    CD47-SIRP alpha-directed

Study groups in NCT05675449
Study groupRoleWhat they receive
Part 1 Dose EscalationExperimentalNon randomized Elranatamab plus Carfilzomib and Dexamethasone
Receives: Drug: Elranatamab; Drug: Carfilzomib
Part 2A Dose EscalationExperimentalNon randomized Elranatamab plus Maplirpacept
Receives: Drug: Elranatamab; Drug: Maplirpacept
Part 2B Dose RandomizationExperimentalRandomized dose level Elranatamab plus Maplirpacept
Receives: Drug: Elranatamab; Drug: Maplirpacept

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part 1 Number of participants with dose limiting toxicity (DLT)

    Dose limiting toxicity rate based on dose limiting toxicity evaluable participants.

    Measured: From first dose of elranatamab through the end of the first cycle of combination treatment, about 42 days.

  2. Part 2A Number of participants with dose limiting toxicity

    Dose limiting toxicity based on dose limiting toxicity evaluable participants.

    Measured: From the first dose of maplirpacept through the first cycle of combination treatment, about 64 days.

  3. Part 2B Number of participants with dose limiting Toxicity

    Dose limiting toxicity rate based on dose limiting toxicity evaluable participants.

    Measured: From first dose of elranatamab through the first cycle of combination treatment, about 42 days.

Secondary outcomes (47)

  1. Part 1: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

    Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

    Measured: Assessed from baseline up to 90 days after last dose of study treatment.

  2. Part 1: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Measured: Assessed from baseline up to 90 days after last dose of study treatment.

  3. Part 1: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity.

    Measured: Accessed from baseline up to 90 days after the last dose of study treatment.

  4. Part 1: Percent of participants with Best Overall Response (BOR)

    BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

    Measured: Assessed for approximately 2 years

  5. Part 1: Percentage of Participants with an Objective Response Rate (ORR)

    ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

    Measured: Assessed from enrollment for approximately 2 years.

  6. Part 1: Percentage of participants with a complete response rate (CRR)

    Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

    Measured: Assessed for approximately 2 years

  7. Part 1: Time to Response (TTR)

    TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

    Measured: Assessed for approximately 2 years.

  8. Part 1: Duration of Response (DOR)

    DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

    Measured: Assessed for approximately 2 years.

  9. Part 1: Duration of Complete Response (DOCR)

    DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

    Measured: Assessed for approximately 2 years.

  10. Part 1: Time of Progression Free Survival (PFS)

    Progression free survival (IMWG response criteria)

    Measured: Assessed from enrollment until Progressive Disease or death for approximately 2 years.

  11. Part 1: Time of Overall Survival (OS)

    OS is the duration of time from first dose of study treatment to death.

    Measured: Assessed for approximately 2 years

  12. Part 1: Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate is the proportion of participants acheiving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

    Measured: Assessed for approximately 2 years

  13. Part 1: Concentrations of carfilzomib

    Pre-dose and post-dose concentrations of cafilzomib

    Measured: Once approximately 7 weeks from enrollment.

  14. Part 1: Concentrations of elranatamab

    Pre-dose and post-dose concentrations of elranatamab

    Measured: Assessed for approximately 2 years.

  15. Part 1: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

    Percent of participants with positive ADA to elranatamab when given in combination with carfilzomib and dexamethasone

    Measured: Assessed for approximately 2 years.

  16. Part 2A: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

    Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

    Measured: Assessed from baseline up to 90 days after last dose of study treatment.

  17. Part 2A: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Measured: Assessed from baseline up to 90 days after last dose of study treatment.

  18. Part 2A: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity.

    Measured: Accessed from baseline up to 90 days after the last dose of study treatment.

  19. Part 2A: Percent of participants with Best Overall Response (BOR)

    BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

    Measured: Assessed for approximately 2 years

  20. Part 2A: Percentage of Participants with an Objective Response Rate (ORR)

    ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

    Measured: Assessed from enrollment for approximately 2 years.

  21. Part 2A: Percentage of participants with a complete response rate (CRR)

    Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

    Measured: Assessed for approximately 2 years

  22. Part 2A: Time to Response (TTR)

    TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

    Measured: Assessed for approximately 2 years.

  23. Part 2A: Duration of Response (DOR)

    DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

    Measured: Assessed for approximately 2 years.

  24. Part 2A: Duration of Complete Response (DOCR)

    DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

    Measured: Assessed for approximately 2 years.

  25. Part 2A: Time of Progression Free Survival (PFS)

    Progression free survival (IMWG response criteria)

    Measured: Assessed from enrollment until Progressive Disease or death for approximately 2 years.

  26. Part 2A: Time of Overall Survival (OS)

    OS is the duration of time from first dose of study treatment to death.

    Measured: Assessed for approximately 2 years

  27. Part 2A: Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate is the proportion of participants achieving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

    Measured: Assessed for approximately 2 years

  28. Part 2A: Concentrations of maplirpacept

    Pre-dose and post-dose concentrations of maplirpacept

    Measured: Assessed for approximately 2 years.

  29. Part 2A: Concentrations of elranatamab

    Pre-dose and post-dose concentrations of elranatamab

    Measured: Assessed for approximately 2 years.

  30. Part 2A: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

    Percent of participants with positive ADA to elranatamab when given in combination with maplirpacept

    Measured: Assessed for approximately 2 years.

  31. Part 2A: Percentage of participants with positive anti-drug antibodies (ADA) against maplirpacept

    Percent of participants with positive ADA to elranatamab when given in combination with elranatamab

    Measured: Assessed for approximately 2 years.

  32. Part 2B: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

    Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

    Measured: Assessed from baseline up to 90 days after last dose of study treatment.

  33. Part 2B: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Measured: Assessed from baseline up to 90 days after last dose of study treatment.

  34. Part 2B: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity.

    Measured: Accessed from baseline up to 90 days after the last dose of study treatment.

  35. Part 2B: Percent of participants with Best Overall Response (BOR)

    BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

    Measured: Assessed for approximately 2 years

  36. Part 2B: Percentage of Participants with an Objective Response Rate (ORR)

    ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

    Measured: Assessed from enrollment for approximately 2 years.

  37. Part 2B: Percentage of participants with a complete response rate (CRR)

    Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

    Measured: Assessed for approximately 2 years

  38. Part 2B: Time to Response (TTR)

    TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

    Measured: Assessed for approximately 2 years.

  39. Part 2B: Duration of Response (DOR)

    DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

    Measured: Assessed for approximately 2 years.

  40. Part 2B: Duration of Complete Response (DOCR)

    DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

    Measured: Assessed for approximately 2 years.

  41. Part 2B: Time of Progression Free Survival (PFS)

    Progression free survival (IMWG response criteria)

    Measured: Assessed from enrollment until Progressive Disease or death for approximately 2 years.

  42. Part 2B: Time of Overall Survival (OS)

    OS is the duration of time from first dose of study treatment to death.

    Measured: Assessed for approximately 2 years

  43. Part 2B: Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate is the proportion of participants achieving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

    Measured: Assessed for approximately 2 years

  44. Part 2B: Concentrations of maplirpacept

    Pre-dose and post-dose concentrations of maplirpacept

    Measured: Assessed for approximately 2 years.

  45. Part 2B: Concentrations of elranatamab

    Pre-dose and post-dose concentrations of elranatamab

    Measured: Assessed for approximately 2 years.

  46. Part 2B: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

    Percent of participants with positive ADA to elranatamab when given in combination with maplirpacept

    Measured: Assessed for approximately 2 years.

  47. Part 2B: Percentage of participants with positive anti-drug antibodies (ADA) against maplirpacept

    Percent of participants with positive ADA to elranatamab when given in combination with elranatamab

    Measured: Assessed for approximately 2 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jan 2023
  2. Study start14 Dec 2022
  3. Primary completion11 Mar 2026
  4. Study completion29 Feb 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
59 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05675449
Sponsor's protocol ID
C1071020
Other IDs
MAGNETISMM-20
Acronym
MagnetisMM-20
Status last verified
Aug 2026
First submitted
7 Dec 2022
Last updated
13 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Elranatamab, Carfilzomib and Maplirpacept in people with Multiple Myeloma, run by Pfizer at 36 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 36 sites in United States, Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part 1 Number of participants with dose limiting toxicity (DLT) (time frame: From first dose of elranatamab through the end of the first cycle of combination treatment, about 42 days.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05675449.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in